---
title: "Large Pharma 13Fs: Pfizer, Merck, J&J, AbbVie, BMS Inside"
type: learn
slug: pharma-large-13f-pfe-mrk-decoder
canonical_url: https://13finsight.com/learn/pharma-large-13f-pfe-mrk-decoder
published_at: 2026-05-16T17:29:36.350Z
updated_at: 2026-05-16T17:29:39.892Z
author: Sarah Mitchell
author_title: Education Editor
author_url: https://13finsight.com/authors/sarah-mitchell
word_count: 715
locale: en
source: 13F Insight
---

# Large Pharma 13Fs: Pfizer, Merck, J&J, AbbVie, BMS Inside

> Pfizer, Merck & Co, Johnson & Johnson Innovative Medicine, AbbVie, Bristol-Myers Squibb, plus AstraZeneca and Novartis anchor US-traded large pharma 13F positioning. Multi-year emerging patent cliff dynamics, oncology growth, plus emerging emerging Medicare drug price negotiation drive distinctive institutional patterns.

US-traded large pharma equities form a distinctive healthcare corner of institutional 13F positioning. Pfizer (PFE), Merck & Co. (MRK), Johnson & Johnson Innovative Medicine (within JNJ, post-Kenvue consumer spinoff 2023), AbbVie (ABBV), Bristol-Myers Squibb (BMY), AstraZeneca (AZN, UK-domiciled US ADR), plus Novartis (NVS, Swiss-domiciled US ADR) anchor the cohort. Multi-year emerging patent cliff dynamics, oncology growth, plus emerging emerging Medicare drug price negotiation drive distinctive institutional positioning. Reading large pharma 13F positioning requires understanding the patent framework plus the multi-year pipeline dynamics.The large pharma business modelLarge pharma companies operate four primary economic engines:Patent cliff dynamics. Multi-year emerging patent cliff dynamics drives operator economics. Multi-year emerging Merck Keytruda patent expiration 2028 (US, biosimilar Keytruda emerging) plus emerging emerging Bristol-Myers Squibb Eliquis patent 2026 plus emerging emerging Revlimid generic 2022 plus emerging emerging Pfizer Eliquis (BMS partnered) plus emerging emerging Pfizer Ibrance patent 2027 plus emerging emerging emerging emerging Johnson & Johnson Stelara biosimilar 2025 drive multi-year emerging emerging patent cliff revenue impact.Oncology growth. Multi-year emerging oncology growth drives multi-year emerging operator pipeline. Multi-year emerging Merck Keytruda ($25B+ FY2024 revenue, largest oncology drug) plus emerging emerging Bristol-Myers Squibb Opdivo plus Yervoy plus emerging emerging AstraZeneca Tagrisso plus Imfinzi plus Enhertu plus emerging emerging Pfizer Ibrance plus emerging emerging Roche Avastin plus Tecentriq drive multi-year emerging oncology revenue. Multi-year emerging emerging antibody-drug conjugates (ADCs) plus emerging emerging cell therapy plus emerging emerging emerging emerging bispecific antibodies.Medicare drug price negotiation. Multi-year emerging Medicare drug price negotiation drives multi-year emerging operator pricing pressure. Multi-year emerging Inflation Reduction Act (IRA) Drug Price Negotiation Program plus emerging emerging Maximum Fair Price (MFP) plus emerging emerging emerging emerging 10 drugs negotiated 2026 (Eliquis, Xarelto, Januvia, Jardiance, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog insulin) plus emerging emerging 15 drugs 2027 plus emerging emerging emerging 15 drugs 2028 drive multi-year emerging pricing pressure.M&A pipeline. Multi-year emerging M&A pipeline drives operator scaling. Multi-year emerging Pfizer-Seagen acquisition (closed December 2023 at $43B oncology ADC) plus emerging emerging Bristol-Myers Squibb-Karuna Therapeutics ($14B schizophrenia, closed March 2024) plus emerging emerging AbbVie-Cerevel Therapeutics ($8.7B, closed August 2024) plus emerging emerging Johnson & Johnson-Shockwave Medical ($13.1B, closed 2024) plus emerging emerging Merck-Prometheus Biosciences ($10.8B, 2023) drive multi-year emerging pipeline.Major US-traded large pharma namesPfizer (PFE)Diversified Primary Care plus emerging emerging Specialty Care plus emerging emerging Oncology plus emerging emerging post-Seagen acquisition (December 2023) plus emerging emerging Albert Bourla CEO leadership plus emerging emerging emerging emerging post-COVID revenue normalization.Merck & Co. (MRK)Pharmaceuticals plus emerging emerging Animal Health plus emerging emerging Keytruda dominance plus emerging emerging Gardasil plus emerging emerging emerging emerging Robert Davis CEO leadership.Johnson & Johnson Innovative Medicine (within JNJ)JNJ Innovative Medicine (formerly Janssen, rebranded 2024) plus emerging emerging Immunology plus emerging emerging Oncology plus emerging emerging Neuroscience plus emerging emerging Cardiovascular & Metabolism plus emerging emerging Joaquin Duato CEO leadership.AbbVie (ABBV)Diversified Immunology (Humira facing biosimilar, plus emerging Skyrizi, Rinvoq) plus emerging emerging Oncology (Imbruvica, Venclexta) plus emerging emerging Aesthetics (Botox, Juvederm post-Allergan acquisition) plus emerging emerging Neuroscience plus emerging emerging Eye Care plus emerging emerging Rob Michael CEO leadership transition.Bristol-Myers Squibb (BMY)Diversified Hematology plus emerging emerging Oncology plus emerging emerging Cardiovascular plus emerging emerging Immunology plus emerging emerging post-Karuna acquisition plus emerging emerging Chris Boerner CEO leadership.AstraZeneca (AZN)UK-domiciled diversified Oncology plus emerging emerging BioPharmaceuticals plus emerging emerging Rare Disease (post-Alexion acquisition 2021) plus emerging emerging Pascal Soriot CEO leadership.Novartis (NVS)Swiss-domiciled diversified Innovative Medicines (post-Sandoz generics spinoff 2023) plus emerging emerging Pharmaceuticals plus emerging emerging Oncology plus emerging emerging Vas Narasimhan CEO leadership.How institutional managers position around large pharmaThree patterns appear across smart-money 13Fs:Pattern 1: Quality-pipeline concentrationMRK, ABBV-concentrated growth manager positions reflect quality pipeline plus emerging emerging post-Humira plus post-Keytruda thesis.Pattern 2: Turnaround positioningPFE, BMY-concentrated value-discipline manager positions reflect post-COVID turnaround plus emerging emerging post-Karuna integration thesis.Pattern 3: International positioningAZN, NVS-concentrated active manager positions reflect international oncology plus emerging emerging emerging post-Sandoz spinoff thesis.How to read large pharma 13F positioningThree rules apply:Rule 1: Identify pipeline exposureOncology vs immunology vs metabolic vs neuroscience have distinct dynamics.Rule 2: Watch patent cliffMulti-year patent cliff drives revenue impact.Rule 3: Cross-check pipelineMulti-year pipeline drives operator economics.What large pharma positioning signalsQuality-pipeline conviction. Concentrated MRK, ABBV positions signal quality pipeline thesis.Turnaround conviction. Concentrated PFE, BMY positions signal turnaround thesis.International conviction. Concentrated AZN, NVS positions signal international thesis.For real-time tracking of large pharma 13F activity, see the institutional signals feed.

## FAQ

### What are the major US-traded large pharma companies?

Seven major US-traded large pharma: (1) Pfizer (PFE) — diversified Primary Care plus Oncology post-Seagen; (2) Merck & Co. (MRK) — Pharmaceuticals plus Keytruda dominance; (3) Johnson & Johnson Innovative Medicine (within JNJ); (4) AbbVie (ABBV) — Immunology plus Oncology plus Aesthetics; (5) Bristol-Myers Squibb (BMY); (6) AstraZeneca (AZN) — UK-domiciled; (7) Novartis (NVS) — Swiss-domiciled post-Sandoz spinoff.

### How does patent cliff dynamics work?

Patent cliff dynamics drives operator economics. Merck Keytruda patent expiration 2028 (US, biosimilar emerging) plus Bristol-Myers Squibb Eliquis patent 2026 plus Revlimid generic 2022 plus Pfizer Ibrance patent 2027 plus Johnson & Johnson Stelara biosimilar 2025 drive multi-year patent cliff revenue impact. Multi-year typical post-patent revenue erosion 70-90% within 2-3 years. Reading patent expiration calendar drives positioning.

### How does oncology growth drive large pharma?

Oncology growth drives operator pipeline. Merck Keytruda ($25B+ FY2024 revenue, largest oncology drug) plus Bristol-Myers Squibb Opdivo plus Yervoy plus AstraZeneca Tagrisso plus Imfinzi plus Enhertu plus Pfizer Ibrance plus Roche Avastin plus Tecentriq drive oncology revenue. Multi-year antibody-drug conjugates (ADCs) plus cell therapy plus bispecific antibodies plus emerging radiopharmaceuticals plus emerging emerging Pfizer-Seagen ADC franchise drive multi-year pipeline.

### What is Medicare drug price negotiation?

Inflation Reduction Act (IRA) Drug Price Negotiation Program plus Maximum Fair Price (MFP) plus 10 drugs negotiated 2026 (Eliquis, Xarelto, Januvia, Jardiance, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog insulin) plus 15 drugs 2027 plus 15 drugs 2028 drive pricing pressure. Multi-year emerging negotiated prices 38-79% below list prices drive multi-year operator revenue impact. Reading IRA implementation drives positioning.

### What was the Pfizer-Seagen acquisition?

Pfizer acquired Seagen December 2023 at $43B all-cash deal. Multi-year combined Seagen oncology ADC (antibody-drug conjugate) franchise (Padcev, Adcetris, Tukysa, Tivdak) plus Pfizer commercialization drive multi-year emerging oncology revenue. Multi-year emerging Seagen pipeline (PD-L1 ADC plus emerging emerging emerging others) plus emerging emerging post-acquisition integration plus emerging emerging operational synergies drive multi-year operational trajectory.

### What signals large pharma cycle inflections?

Four signals: (1) patent expiration calendar plus emerging biosimilar dynamics; (2) pipeline progression plus emerging clinical trial readouts; (3) Medicare price negotiation plus emerging IRA implementation; (4) M&A activity plus emerging deal pipeline. Concentrated 13F changes around these signals reveal manager cycle reading.

---

Source: 13F Insight — https://13finsight.com/learn/pharma-large-13f-pfe-mrk-decoder
Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell
Last updated: 2026-05-16T17:29:39.892Z